LMRI Stock Analysis: Lumexa Imaging Holdings | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.194m USD | 12M Return: -35.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.21M
Rev. Trend: 92.9%
Warnings
Tailwinds
Seasonality 0.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Lumexa Imaging Holdings, Inc. (LMRI) is a North Carolina-based healthcare provider specializing in outpatient diagnostic imaging services. Founded in 2018, the company operates centers across the United States that offer a range of advanced modalities, including MRI, CT, and PET scans, alongside routine screenings such as X-rays, ultrasounds, and mammography.
The diagnostic imaging sector operates within the broader Health Care Services industry, where revenue is largely driven by physician referrals and reimbursement rates from private insurers and government programs. This business model relies on high capital expenditure for medical equipment, balanced by the recurring demand for non-invasive diagnostic tools in preventative care and chronic disease management.
Investors can further evaluate these industry fundamentals and company-specific metrics by exploring ValueRay.
- Expansion of outpatient imaging centers drives regional market share and revenue growth
- Medicare and private insurance reimbursement rate changes impact net operating margins
- High capital expenditure for MRI and CT technology updates affects free cash flow
- Rising demand for preventative screening services increases diagnostic procedure volume
- Labor costs for specialized radiologic technologists influence overall facility profitability
| Net Income: -59.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.09 > 1.0 |
| NWC/Revenue: 6.31% < 20% (prev -0.12%; Δ 6.43% < -1%) |
| CFO/TA 0.02 > 3% & CFO 31.4m > Net Income -59.7m |
| Net Debt (1.05b) to EBITDA (78.9m): 13.34 < 3 |
| Current Ratio: 1.40 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (71.0m) vs prev -24.94% < -2% |
| Gross Margin: 11.13% > 18% (prev 10.15%; Δ 0.98% > 0.5%) |
| Asset Turnover: 58.31% > 50% (prev 55.41%; Δ 2.89% > 0%) |
| Interest Coverage Ratio: 0.21 > 6 (EBIT TTM 22.4m / Interest Expense TTM 105.6m) |
| A: 0.04 (Total Current Assets 221.9m - Total Current Liabilities 157.9m) / Total Assets 1.76b |
| B: -0.36 (Retained Earnings -629.3m / Total Assets 1.76b) |
| C: 0.01 (EBIT TTM 22.4m / Avg Total Assets 1.74b) |
| D: 0.52 (Book Value of Equity 599.6m / Total Liabilities 1.16b) |
| Altman-Z'' = -0.30 = B |
| DSRI: 1.06 (Receivables 154.1m/136.0m, Revenue 1.01b/948.9m) |
| GMI: 0.91 (GM 10.15% / 11.13%) |
| AQI: 0.95 (AQ_t 0.75 / AQ_t-1 0.78) |
| SGI: 1.07 (Revenue 1.01b / 948.9m) |
| TATA: -0.05 (NI -59.7m - CFO 31.4m) / TA 1.76b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 12.00 with a total of 328,460 shares traded. Over the past week, the price has changed by -3.46%, over one month by +32.74%, over three months by +28.76% and over the past year by -35.21%.
Current recommended Stop Loss: 11.00 (which is 8.3% or 1.3 ATR below the current price).
Lumexa Imaging Holdings has no consensus analysts rating.
P/S = 1.1588
P/B = 1.9917
Revenue TTM = 1.01b USD
EBIT TTM = 22.4m USD
EBITDA TTM = 78.9m USD
Long Term Debt = 817.0m USD (from longTermDebt, last quarter)
Short Term Debt = 40.6m USD (from shortTermDebt, last quarter)
Debt = 1.10b USD (from shortLongTermDebtTotal, last quarter) + Leases 135.3m
Net Debt = 1.05b USD (calculated: Debt 1.10b - CCE 51.2m)
Enterprise Value = 2.25b USD (1.19b + Debt 1.10b - CCE 51.2m)
Interest Coverage Ratio = 0.21 (Ebit TTM 22.4m / Interest Expense TTM 105.6m)
EV/FCF = 150.2x (Enterprise Value 2.25b / FCF TTM 14.9m)
FCF Yield = 0.67% (FCF TTM 14.9m / Enterprise Value 2.25b)
FCF Margin = 1.48% (FCF TTM 14.9m / Revenue TTM 1.01b)
Net Margin = -5.89% (Net Income TTM -59.7m / Revenue TTM 1.01b)
Gross Margin = 11.13% ((Revenue TTM 1.01b - Cost of Revenue TTM 900.5m) / Revenue TTM)
Gross Margin QoQ = 9.84% (prev 11.10%)
Tobins Q-Ratio = 1.27 (Enterprise Value 2.25b / Total Assets 1.76b)
Interest Expense / Debt = 9.57% (Interest Expense 105.6m / Debt 1.10b)
Taxrate = 44.27% (1.36m / 3.08m)
NOPAT = 12.5m (EBIT 22.4m * (1 - 44.27%))
Current Ratio = 1.40 (Total Current Assets 221.9m / Total Current Liabilities 157.9m)
Debt / Equity = 1.84 (Debt 1.10b / totalStockholderEquity, last quarter 599.6m)
Debt / EBITDA = 13.34 (Net Debt 1.05b / EBITDA 78.9m)
Debt / FCF = 70.34 (Net Debt 1.05b / FCF TTM 14.9m)
Total Stockholder Equity = 378.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.44% (Net Income -59.7m / Total Assets 1.76b)
RoE = -15.77% (Net Income TTM -59.7m / Total Stockholder Equity 378.6m)
RoCE = 1.87% (EBIT 22.4m / Capital Employed (Equity 378.6m + L.T.Debt 817.0m))
RoIC = 0.78% (NOPAT 12.5m / Invested Capital 1.60b)
WACC = 6.53% (E(1.19b)/V(2.30b) * Re(7.63%) + D(1.10b)/V(2.30b) * Rd(9.57%) * (1-Tc(0.44)))
Discount Rate = 7.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 31.62 | Cagr: 1.50%
[DCF] Terminal Value 77.97% ; FCFF base≈14.2m ; Y1≈16.2m ; Y5≈23.9m
[DCF] Fair Price = N/A (negative equity: EV 359.3m - Net Debt 1.05b = -692.3m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 92.87 | Revenue CAGR: 4.55% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.14 | Chg30d=+1.41% | Revisions=-38% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.19 | Chg30d=+1.05% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=0.71 | Chg30d=+0.57% | Revisions=+0% | GrowthEPS=+293.2% | GrowthRev=+4.2%
EPS next Year (2027-12-31): EPS=0.90 | Chg30d=+0.67% | Revisions=+0% | GrowthEPS=+27.5% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: -15% (up=7, down=10)